title: Nephroprotective effects of hydration with magnesium in patients with cervical cancer receiving cisplatin.
abstract: OBJECTIVE
  The present study aimed to assess the efficacy of 15 mEq magnesium supplied as part of a prehydration regimen in preventing cisplatin-induced nephrotoxicity in patients undergoing therapy with cisplatin-alone (40 mg/m(2)/week) for cervical cancer.
  
  
  METHODS
  We studied 28 patients with cervical cancer. This prospective cohort study compared nephrotoxicity in patients who received hydration with and without magnesium sulfate (Mg-hydration group, n=14; non-Mg-hydration group, n=14).
  
  
  RESULTS
  Baseline characteristics, stage of cervical cancer, cisplatin dose and renal function did not differ significantly between the two groups. The serum creatinine level significantly increased from 0.58 to 0.75 mg/dl, and the estimated glomerular filtration rate significantly decreased from 85.1 to 66.5 ml/min by chemotherapy in the non-Mg-hydration group. In contrast, these levels did not change significantly in the Mg-hydration group.
  
  
  CONCLUSIONS
  A magnesium dose of 15 mEq was found to provide nephroprotective effects among patients with cervical cancer undergoing chemotherapy with cisplatin alone.
authors: Department of Pharmacy, Aichi Medical University School of Medicine, Aichi, Japan yamamo_0308@yahoo.co.jp.
authors: Yoshihiro
authors: Y
authors: Yamamoto
authors: Department of Obstetrics and Gynecology, Aichi Medical University School of Medicine, Aichi, Japan.
authors: Kazushi
authors: K
authors: Watanabe
authors: Department of Pharmacy, Aichi Medical University School of Medicine, Aichi, Japan.
authors: Ikuto
authors: I
authors: Tsukiyama
authors: Department of Obstetrics and Gynecology, Aichi Medical University School of Medicine, Aichi, Japan.
authors: Hiroshi
authors: H
authors: Matsushita
authors: Department of Obstetrics and Gynecology, Aichi Medical University School of Medicine, Aichi, Japan.
authors: Hiromitsu
authors: H
authors: Yabushita
authors: Department of Pharmacy, Aichi Medical University School of Medicine, Aichi, Japan.
authors: Katsuhiko
authors: K
authors: Matsuura
authors: Department of Obstetrics and Gynecology, Aichi Medical University School of Medicine, Aichi, Japan.
authors: Akihiko
authors: A
authors: Wakatsuki
mesh_terms: D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053565:Hypercalciuria / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D055103:Hypodermoclysis; D007668:Kidney / Q000187:drug effects; D008274:Magnesium / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009397:Nephrocalcinosis / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D051437:Renal Insufficiency / Q000139:chemically induced / Q000188:drug therapy*; D015499:Renal Tubular Transport, Inborn Errors / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D008274:Magnesium; D002945:Cisplatin
keywords: cervical cancer; cisplatin; hydration; magnesium; nephrotoxicity